The natural history of chronic obstructive pulmonary disease

Hot Topics in Respiratory Medicine

Volumn 4, Issue 11, 2009, Pages 7-14

  Mannino, David M ^a   Hudson, Naomi L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AGING; ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COST OF ILLNESS; COUGHING; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; FORCED EXPIRATORY VOLUME; GENETIC SUSCEPTIBILITY; HEALTH CARE COST; HUMAN; INFLAMMATION; LUNG FUNCTION; MORBIDITY; MORTALITY; PHENOTYPE; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING; SPIROMETRY; SPUTUM;

EID: 77953377673     PISSN: 19739664     EISSN: 20360886     Source Type: Book Series    
DOI: None     Document Type: Review

References (97)

1. Mannino DM, Watt G, Hole D, et al. The global burden of chronic obstructive pulmonary disease, number 3: The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006;27:627-643. (Pubitemid 43372539)
2. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-750. (Pubitemid 47321907)
3. Mannino DM, Buist AS, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007;62:237-241. (Pubitemid 46579804)
4. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-1259.
5. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ 2002;51:1-16.
6. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global burden of disease and risk factors. Washington, DC: The World Bank, 2006.
7. Burrows B, Strauss RH, Niden AH. Chronic obstructive lung disease. 3. Interrelationships of pulmonary function data. Am Rev Respir Dis 1965;91:861-868.
8. Fletcher C, Peto R, Tinker CM, Speizer FE. The natural history of chronic bronchitis and emphysema. London: Oxford University Press, 1976.
9. Peto R, Speizer FE, Cochrane AL, et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983;128:491-500.
10. Anthonisen NR. The British hypothesis revisited. Eur Respir J 2004;23:657-658.
11. Vestbo J, Prescott E. Update on the "Dutch hypothesis" for chronic respiratory disease. Thorax 1998;53(Suppl 2):S15-S19. (Pubitemid 28408751)
12. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008;31:869-873.
13. Molfino NA, Coyle AJ. Gene-environment interactions in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:491-497.
14. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555. (Pubitemid 47403272)
15. Barnes PJ. Medical progress: Chronic obstructive pulmonary disease. New Engl J Med 2000;343:269-280.
16. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-968. (Pubitemid 41632054)
17. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946. (Pubitemid 38807371)
18. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax 2005;60:842-847. (Pubitemid 41475212)
19. Kim SJ, Suk MH, Choi HM, et al. The local prevalence of COPD by post-bronchodilator GOLD criteria in Korea. Int J Tuberc Lung Dis 2006;10:1393-1398.
20. 1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008;63:1046-1051.
21. Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006;100:115-122.
22. Celli BR, Halbert RJ, Nordyke RJ, Schau B. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 2005;118:1364-1372. (Pubitemid 41832329)
23. Bakke PS, Baste V, Hanoa R, Gulsvik A. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax 1991;46:863-870.
24. Peat JK, Woolcock AJ, Cullen K. Decline of lung function and development of chronic airflow limitation: a longitudinal study of non-smokers and smokers in Busselton, Western Australia. Thorax 1990;45:32-37. (Pubitemid 20046487)
25. Liu Y, Lee K, Perez-Padilla R, Hudson NL, Mannino DM. Outdoor and indoor air pollution and COPD-related diseases in high- and low-income countries. Int J Tuberc Lung Dis 2008;12:115-127. (Pubitemid 351212402)
26. Bartal M. COPD and tobacco smoke. Monaldi Arch Chest Dis 2005;63:213-225.
27. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001;2:20-26. (Pubitemid 34187903)
28. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003;22:462-469. (Pubitemid 37098927)
29. Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007;62:889-897. (Pubitemid 47598354)
30. Jaakkola JJ, Kosheleva AA, Katsnelson BA, Kuzmin SV, Privalova LI, Spengler JD. Prenatal and postnatal tobacco smoke exposure and respiratory health in Russian children. Respir Res 2006;7:48.
31. de Marco R, Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004;59:120-125. (Pubitemid 38223482)
32. Balmes J, Becklake M, Blanc P, et al. American Thoracic Society Statement: occupational contribution to the burden of airway disease. Am J Respir Crit Care Med 2003;167:787-797.
33. Blanc PD, Iribarren C, Trupin L, et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009;64:6-12.
34. DeMeo DL, Carey VJ, Chapman HA, et al. Familial aggregation of FEF (25-75) and FEF (25-75)/FVC in families with severe, early onset COPD. Thorax 2004;59:396-400.
35. Caramori G, Adcock I. Gene-environment interactions in the development of chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 2006;6:323-328. (Pubitemid 44368237)
36. Brehm JM, Celedon JC. Chronic obstructive pulmonary disease in Hispanics. Am J Respir Crit Care Med 2008;177:473-478.
37. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008;63:761-767.
38. Postma DS, Lebowitz MD. Persistence and new onset of asthma and chronic bronchitis evaluated longitudinally in a community population sample of adults. Arch Intern Med 1995;155:1393-1399.
39. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-1200. (Pubitemid 28482128)
40. Petty TL. COPD: clinical phenotypes. Pulm Pharmacol Ther 2002;15:341-351.
41. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276. (Pubitemid 32378468)
42. Downs CA, Appel SJ. Chronic obstructive pulmonary disease: diagnosis and management. J Am Acad Nurse Pract 2007;19:126-132.
43. Girod CE, King TE Jr. COPD: a dust-induced disease? Chest 2005;128:3055-3064.
44. Borish L, Culp JA. Asthma: a syndrome composed of heterogeneous diseases. Ann Allergy Asthma Immunol 2008;101:1-8. (Pubitemid 352000737)
45. Kelley CF, Mannino DM, Homa DM, Savage-Brown A, Holguin F. Asthma phenotypes, risk factors, and measures of severity in a national sample of US children. Pediatrics 2005;115:726-731. (Pubitemid 43373035)
46. Friedlander AL, Lynch D, Dyar LA, Bowler RP. Phenotypes of chronic obstructive pulmonary disease. COPD 2007;4:355-384. (Pubitemid 350135871)
47. Rennard SI, Vestbo J. The many "small COPDs": COPD should be an orphan disease. Chest 2008;134:623-627.
48. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;528:523-532. (Pubitemid 44794666)
49. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773.
50. Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc 2006;3:619-623. (Pubitemid 44411630)
51. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000;160:1683-1689.
52. Han MK, Postma D, Mannino DM, et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med 2007;176:1179-1184. (Pubitemid 350256470)
53. Abramson M, Matheson M, Wharton C, Sim M, Walters EH. Prevalence of respiratory symptoms related to chronic obstructive pulmonary disease and asthma among middle aged and older adults. Respirology 2002;7:325-331.
54. Cohen SBZ, Pare PD, Man SFP, Sin DD. The growing burden of chronic obstructive pulmonary disease and lung cancer in women. Am J Respir Crit Care Med 2007;176:113-120.
55. Engstrom CP, Persson LO, Larsson S, Sullivan M. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001;18:69-76. (Pubitemid 32717433)
56. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
57. Carrasco GP, de Miguel DJ, Rejas GJ, et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes 2006;4:31.
58. Ferrer M, Villasante C, Alonso J, et al. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J 2002;19:405-413. (Pubitemid 34256952)
59. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13.
60. Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006;7:62. (Pubitemid 44043186)
61. Michaud CM, Murray CJ, Bloom BR. Burden of disease - implications for future research. JAMA 2001;285:535-539.
62. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-1243.
63. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20. (Pubitemid 16189089)
64. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006;61:250-258.
65. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-255. (Pubitemid 46203128)
66. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1298-1303. (Pubitemid 39571857)
67. 1. The Lung Health Study. JAMA 1994;272:1497-1505.
68. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422. (Pubitemid 28242071)
69. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303. (Pubitemid 30245717)
70. Ko FW, Hui DS, Lai CK. Worldwide burden of COPD in high- and low-income countries. Part III. Asia-Pacific studies. Int J Tuberc Lung Dis 2008;12:713-717.
71. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-564. (Pubitemid 47547851)
72. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997;156:814-818.
73. Hansell A, Hollowell J, McNiece R, Nichols T, Strachan D. Validity and interpretation of mortality, health service and survey data on COPD and asthma in England. Eur Respir J 2003;21:279-286. (Pubitemid 36204543)
74. Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J 2006;28:781-785. (Pubitemid 46331999)
75. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006;28:1245-1257.
76. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991;133:795-800.
77. Vilkman S, Keistinen T, Tuuponen T, Kivela SL. Population ageing will lead to an increase in hospitalisation for chronic illnesses like asthma and COPD [letter]. Scand J Soc Med 1997;25:26-27. (Pubitemid 127718136)
78. Zielinski J, MacNee W, Wedzicha J, et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997;52:43-47. (Pubitemid 27232210)
79. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412. (Pubitemid 43180921)
80. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S.
81. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:502-506. (Pubitemid 47547843)
82. Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 2006;51:1120-1124.
83. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006;61:472-477. (Pubitemid 43901515)
84. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613. (Pubitemid 30329036)
85. Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med 2006;173:985-990.
86. Mannino DM, Holguin F, Pavlin BI, Ferdinands JM. Risk factors for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis 2005;9:613-621. (Pubitemid 40826152)
87. Schneider A, Gantner L, Maag I, Borst MM, Wensing M, Szecsenyi J. Are ICD-10 codes appropriate for performance assessment in asthma and COPD in general practice? Results of a cross sectional observational study. BMC Health Serv Res 2005;5:11. (Pubitemid 40393486)
88. Mannino DM. Should we be using statistics to define disease? Thorax 2008;63:1031-1032.
89. 1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008;63:1040-1045.
90. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:235-256.
91. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008;63:599-605.
92. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005-2011.
93. Minakata Y, Sugiura H, Yamagata T, et al. Prevalence of COPD in primary care clinics: correlation with non-respiratory diseases. Intern Med 2008;47:77-82.
94. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Gig Harbor, WA: Medical Communications Resources, Inc; 2008. [Accessed 2008 April 9. Available from: www.goldcopd.org.]
95. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J 2008;32:962-969.
96. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New Engl J Med 2004;350:1005-1012. (Pubitemid 38269277)
97. Celli BR. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 2006;3:58-65. (Pubitemid 43304380)